Aytu biopharma announces sale of consumer health business following wind down of consumer health operations

Consumer health wind down and sale maximizes shareholder value as company focuses on rx segment eliminates materially all remaining expenses associated with the consumer health business provides for receipt of future sales-based royalty payments denver, co / accesswire / august 6, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced that following the wind down of operations, it has entered into a definitive agreement to divest its consumer health (a/k/a innovus pharmaceuticals) business to a private, e-commerce focused company. the divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for aytu to receive revenue-based royalty payments on future sales of former consumer health business products.
AYTU Ratings Summary
AYTU Quant Ranking